Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (FUTURE 1 ext)
maanantai 20. toukokuuta 2019 päivittänyt: Novartis Pharmaceuticals
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
This study was designed as a 3-year extension to the phase III core study CAIN457F2306.
It aimed to provide continuous treatment with secukinumab in pre-filled syringes (PFS) for subjects who completed the core study CAIN457F2306, to obtain further long term efficacy, safety and tolerability information in subjects with active psoriatic arthritis receiving secukinumab every 4 weeks.
At Week 104 of the study CAIN457F2306, eligible subjects completed the assessments associated with the core study visit and subsequently continued in this extension study on the same dose that they were receiving during the core study.
The regular assessments of disease activity ensure that subjects who are experienced worsening of disease in any of the treatment groups could exit the study upon their own wish or based on the advice of the investigator at any time.
Tutkimuksen yleiskatsaus
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
460
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
-
Buenos Aires, Argentiina, C1417EYG
- Novartis Investigative Site
-
Caba, Argentiina, C1419AHN
- Novartis Investigative Site
-
Cordoba, Argentiina, X5016KEH
- Novartis Investigative Site
-
Córdoba, Argentiina, X5000EDC
- Novartis Investigative Site
-
-
Buenos Aires
-
Caba, Buenos Aires, Argentiina, C1181ACH
- Novartis Investigative Site
-
-
Santa Fe
-
Rosario, Santa Fe, Argentiina, S2000CFJ
- Novartis Investigative Site
-
-
-
-
Queensland
-
Maroochydore, Queensland, Australia, 4558
- Novartis Investigative Site
-
-
Victoria
-
Malvern East, Victoria, Australia, 3145
- Novartis Investigative Site
-
-
-
-
-
Genk, Belgia, 3600
- Novartis Investigative Site
-
Gent, Belgia, 9000
- Novartis Investigative Site
-
Leuven, Belgia, 3000
- Novartis Investigative Site
-
-
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brasilia, 90610-000
- Novartis Investigative Site
-
-
SP
-
Sao Paulo, SP, Brasilia, 04023-900
- Novartis Investigative Site
-
Sao Paulo, SP, Brasilia, 04266 010
- Novartis Investigative Site
-
-
-
-
-
Pleven, Bulgaria, 5800
- Novartis Investigative Site
-
Sofia, Bulgaria, 1612
- Novartis Investigative Site
-
-
Gabrovo
-
Sevlievo, Gabrovo, Bulgaria, 5400
- Novartis Investigative Site
-
-
-
-
-
Las Pinas, Filippiinit, 1740
- Novartis Investigative Site
-
Manila, Filippiinit, 1003
- Novartis Investigative Site
-
Manila, Filippiinit, 1008
- Novartis Investigative Site
-
Quezon City, Filippiinit, 1102
- Novartis Investigative Site
-
Quezon City, Filippiinit, 1118
- Novartis Investigative Site
-
-
Batangas
-
Lipa City, Batangas, Filippiinit, 4217
- Novartis Investigative Site
-
-
Cavite
-
Dasmarinas, Cavite, Filippiinit, 4114
- Novartis Investigative Site
-
-
Metro Manila
-
Manila, Metro Manila, Filippiinit, 1003
- Novartis Investigative Site
-
-
-
-
-
Ashkelon, Israel, 78278
- Novartis Investigative Site
-
Haifa, Israel, 3339419
- Novartis Investigative Site
-
Ramat Gan, Israel, 5265601
- Novartis Investigative Site
-
Tel Aviv, Israel, 6423906
- Novartis Investigative Site
-
-
-
-
CT
-
Catania, CT, Italia, 95100
- Novartis Investigative Site
-
-
PO
-
Prato, PO, Italia, 59100
- Novartis Investigative Site
-
-
SI
-
Siena, SI, Italia, 53100
- Novartis Investigative Site
-
-
VR
-
Verona, VR, Italia, 37134
- Novartis Investigative Site
-
-
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Kanada, A1C 5B8
- Novartis Investigative Site
-
St. John's, Newfoundland and Labrador, Kanada, A1A 5E8
- Novartis Investigative Site
-
-
Ontario
-
Newmarket, Ontario, Kanada, L3Y 3R7
- Novartis Investigative Site
-
Waterloo, Ontario, Kanada, N2J 1C4
- Novartis Investigative Site
-
-
Quebec
-
Trois-Rivieres, Quebec, Kanada, G8Z 1Y2
- Novartis Investigative Site
-
-
-
-
-
Bialystok, Puola, 15-351
- Novartis Investigative Site
-
Warszawa, Puola, 02-341
- Novartis Investigative Site
-
-
-
-
-
Aachen, Saksa, 52064
- Novartis Investigative Site
-
Erlangen, Saksa, 91054
- Novartis Investigative Site
-
Erlangen, Saksa, 91056
- Novartis Investigative Site
-
Gommern, Saksa, 39245
- Novartis Investigative Site
-
Hamburg, Saksa, 22415
- Novartis Investigative Site
-
Hildesheim, Saksa, 31134
- Novartis Investigative Site
-
Koeln, Saksa, 50937
- Novartis Investigative Site
-
Leipzig, Saksa, 04103
- Novartis Investigative Site
-
Nürnberg, Saksa, 90429
- Novartis Investigative Site
-
Ratingen, Saksa, 40878
- Novartis Investigative Site
-
Zerbst, Saksa, 39261
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapore, 119074
- Novartis Investigative Site
-
Singapore, Singapore, 529889
- Novartis Investigative Site
-
Singapore, Singapore, 169608
- Novartis Investigative Site
-
-
-
-
-
Lucenec, Slovakia, 984 01
- Novartis Investigative Site
-
-
-
-
-
Bangkok, Thaimaa, 10400
- Novartis Investigative Site
-
Chiang Mai, Thaimaa, 50200
- Novartis Investigative Site
-
-
THA
-
Khon Kaen, THA, Thaimaa, 40002
- Novartis Investigative Site
-
-
-
-
Czech Republic
-
Bruntal, Czech Republic, Tšekki, 792 01
- Novartis Investigative Site
-
Uherske Hradiste, Czech Republic, Tšekki, 686 01
- Novartis Investigative Site
-
Zlin, Czech Republic, Tšekki, 760 01
- Novartis Investigative Site
-
-
-
-
-
Ekaterinburg, Venäjän federaatio, 620109
- Novartis Investigative Site
-
Ekaterinburg, Venäjän federaatio, 620028
- Novartis Investigative Site
-
Kemerovo, Venäjän federaatio, 650029
- Novartis Investigative Site
-
Moscow, Venäjän federaatio, 115522
- Novartis Investigative Site
-
St Petersburg, Venäjän federaatio, 190068
- Novartis Investigative Site
-
Yaroslavl, Venäjän federaatio, 150003
- Novartis Investigative Site
-
-
-
-
-
Glasgow, Yhdistynyt kuningaskunta, G31 2ER
- Novartis Investigative Site
-
London, Yhdistynyt kuningaskunta, SE1 9RT
- Novartis Investigative Site
-
-
London
-
Leytonstone, London, Yhdistynyt kuningaskunta, E11 1NR
- Novartis Investigative Site
-
-
Staffordshire
-
Cannock, Staffordshire, Yhdistynyt kuningaskunta, WS11 2XY
- Novartis Investigative Site
-
-
West Yorkshire
-
Bradford, West Yorkshire, Yhdistynyt kuningaskunta, BD5 0NA
- Novartis Investigative Site
-
-
-
-
Alabama
-
Anniston, Alabama, Yhdysvallat, 36207-5710
- Novartis Investigative Site
-
-
Arizona
-
Mesa, Arizona, Yhdysvallat, 85202
- Novartis Investigative Site
-
Paradise Valley, Arizona, Yhdysvallat, 85253
- Novartis Investigative Site
-
-
California
-
Upland, California, Yhdysvallat, 91786
- Novartis Investigative Site
-
-
Florida
-
Tamarac, Florida, Yhdysvallat, 33321
- Novartis Investigative Site
-
-
Minnesota
-
Eagan, Minnesota, Yhdysvallat, 55121
- Novartis Investigative Site
-
-
Missouri
-
Saint Louis, Missouri, Yhdysvallat, 63117
- Novartis Investigative Site
-
-
Nebraska
-
Lincoln, Nebraska, Yhdysvallat, 68516
- Novartis Investigative Site
-
-
New Jersey
-
Freehold, New Jersey, Yhdysvallat, 07728
- Novartis Investigative Site
-
-
North Carolina
-
Charlotte, North Carolina, Yhdysvallat, 28210
- Novartis Investigative Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Yhdysvallat, 73103
- Novartis Investigative Site
-
-
Pennsylvania
-
Duncansville, Pennsylvania, Yhdysvallat, 16635
- Novartis Investigative Site
-
-
South Carolina
-
Charleston, South Carolina, Yhdysvallat, 29460
- Novartis Investigative Site
-
Columbia, South Carolina, Yhdysvallat, 29204
- Novartis Investigative Site
-
-
Tennessee
-
Jackson, Tennessee, Yhdysvallat, 38305
- Novartis Investigative Site
-
-
Texas
-
Benbrook, Texas, Yhdysvallat, 76126
- Novartis Investigative Site
-
Dallas, Texas, Yhdysvallat, 75216
- Novartis Investigative Site
-
Dallas, Texas, Yhdysvallat, 75246
- Novartis Investigative Site
-
Houston, Texas, Yhdysvallat, 77074
- Novartis Investigative Site
-
League City, Texas, Yhdysvallat, 77573
- Novartis Investigative Site
-
Mesquite, Texas, Yhdysvallat, 75150
- Novartis Investigative Site
-
-
Washington
-
Seattle, Washington, Yhdysvallat, 98122
- Novartis Investigative Site
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Ei
Sukupuolet, jotka voivat opiskella
Kaikki
Kuvaus
Inclusion criteria
- Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study assessment is performed
- Subjects must have participated in core study CAIN457F2306, and must have completed the entire treatment period
- Subjects must be deemed by the investigator to benefit from continued secukinumab therapy
Exclusion criteria
- Any subject taking other concomitant biologic immunomodulating agent(s) except secukinumab
- Any subject who is deemed not to be benefiting from the study treatment based upon lack of improvement or worsening of their symptoms
- Pregnant or nursing (lactating) women
- Women of child-bearing potential, unless they are using effective methods of contraception during the entire study or longer if required by locally approved prescribing information (e.g., 20 weeks in EU)
Other protocol-defined inclusion/exclusion criteria may apply
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Secukinumab 75mg
Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256.
From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator
|
Secukinumab is a human monoclonal antibody.
Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces.
Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17).
Muut nimet:
|
|
Kokeellinen: Secukinumab 150mg
Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256.
From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator
|
Secukinumab is a human monoclonal antibody.
Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces.
Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17).
Muut nimet:
|
|
Kokeellinen: Placebo - AIN457A 75mg
Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5 mL solution solution for injection was provided in PFS for s.c.
administration (a single use pre-filled 1mL long glass syringe).
It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg
|
Plasebo
Muut nimet:
Secukinumab is a human monoclonal antibody.
Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces.
Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17).
Muut nimet:
|
|
Kokeellinen: Placebo - AIN457 150mg
Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1 mL solution for injection was provided in PFS for s.c.
administration (a single use pre-filled 1mL long glass syringe).
It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg
|
Plasebo
Muut nimet:
Secukinumab is a human monoclonal antibody.
Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces.
Secukinumab binds and reduces the activity of a cytokine (a "messenger" protein in the body) called Interleukin 17 (IL-17).
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Proportion of Subject Who Reached (American College of Rheumatology Score of 20) ACR20
Aikaikkuna: weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
Proportion of subjects with a positive clinical response to treatment (individual improvement) in disease activity according to ACR20 criteria if he/she has at least 20% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:
|
weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
|
Proportion of Subjects Who Reached ACR50
Aikaikkuna: weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR50 criteria if he/she has at least 50% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:
|
weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
|
Proportion of Subjects Who Reached ACR70
Aikaikkuna: weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR70 criteria if he/she has at least 70% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:- Patient's assessment of PsA pain
|
weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
Aikaikkuna: weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
Changes from baseline in score of the disability assessment component of the HAQ (Health Assessment Questionnaire - Disability Index). The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. Health Assessment Questionnaire - Disability Index (HAQ-DI) ranges from 0 (no disability) to 3 (very severe disability) |
weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
|
Minimal Clinically Important Difference (MCID) in Health Assessment Questionnaire Disability Index (HAQ-DI)
Aikaikkuna: weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
Percentage of subjects with improvements from baseline in HAQ-DI meeting or exceeding minimal clinically important difference (MCID=0.3).
The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.
|
weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
|
Change From Baseline in Disease Activity Score-CRP (DAS28)
Aikaikkuna: weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
Changes in DAS28 (utilizing hsCRP) from baseline up to Month 60. The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. This measure represents change in scores - not the actual scores. DAS28 is a combined measure of disease activity based on the following formula: DAS28-CRP = 0.56*TJC28^0.5 + 0.28*SJC28^0.5 + 0.36*ln(CRP+1) + 0.014*PGA + 0.96 The greater the score is, the more the disease activity exists. Remission is defined as DAS28-CRP < 2.6 Low disease activity is defined as DAS28-CRP < 3.2 The minimum value can be 0.96 (not applicable in our study due to the inclusion/exclusion criteria regarding tender, swollen joints). There is no maximum expected value for this score |
weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
|
Percentage of Subjects Achieving Low Disease Activity
Aikaikkuna: weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
Percentage of subjects achieving low disease activity (DAS28 ≤ 3.2).
The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity.
A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission
|
weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
|
Percentage of Subjects Achieving Disease Remission (DAS28<2.6)
Aikaikkuna: weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
Percentage of subjects achieving disease remission (DAS28<2.6).
The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity.
A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission
|
weeks 116, 128, 140, 156, 180, 208, 232 and 260
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Maanantai 30. syyskuuta 2013
Ensisijainen valmistuminen (Todellinen)
Torstai 11. tammikuuta 2018
Opintojen valmistuminen (Todellinen)
Torstai 11. tammikuuta 2018
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Maanantai 1. heinäkuuta 2013
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Maanantai 1. heinäkuuta 2013
Ensimmäinen Lähetetty (Arvio)
Torstai 4. heinäkuuta 2013
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Keskiviikko 12. kesäkuuta 2019
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Maanantai 20. toukokuuta 2019
Viimeksi vahvistettu
Keskiviikko 1. toukokuuta 2019
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- CAIN457F2306E1
- 2013-001241-13 (EudraCT-numero)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
PÄÄTTÄMÄTÖN
IPD-suunnitelman kuvaus
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Joo
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .